Order Article Reprints

Vasiliadou I, Breik O, Baker H, Leslie I, Sim VR, Hegarty G, Michaelidou A, Nathan K, Hartley A, Good J, et al. Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers. 2021; 13(6):1413. https://doi.org/10.3390/cancers13061413

Vasiliadou, Ifigenia, Omar Breik, Holly Baker, Isla Leslie, Van Ren Sim, Gemma Hegarty, Andriana Michaelidou, Kannon Nathan, Andrew Hartley, James Good, and et al. 2021. "Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study" Cancers 13, no. 6: 1413. https://doi.org/10.3390/cancers13061413

Vasiliadou, I., Breik, O., Baker, H., Leslie, I., Sim, V. R., Hegarty, G., Michaelidou, A., Nathan, K., Hartley, A., Good, J., Sanghera, P., Fong, C., Urbano, T. G., Lei, M., Petkar, I., Ferreira, M. R., Nutting, C., Wong, K. H., Newbold, K., ... Kong, A. (2021). Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 13(6), 1413. https://doi.org/10.3390/cancers13061413